Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Journal of Global Antimicrobial Resistance|November 23, 2016
Action Plan to combat infections due to carbapenem-resistant, Gram-negative pathogens in acute-care hospitals in GreeceHelena C Maltezou, Flora Kontopidou, Xanthi Dedoukou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 19, 2021
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)Mical Paul, Elena Carrara, Pilar Retamar, et al.
Jac-Antimicrobial Resistance|July 29, 2025
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)George L Daikos, José Miguel Cisneros, Yehuda Carmeli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2018
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical TrialYaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar, et al.
Antioxidants (Basel, Switzerland)|February 25, 2022
Oxidant/Antioxidant Status Is Impaired in Sepsis and Is Related to Anti-Apoptotic, Inflammatory, and Innate Immunity AlterationsMarianna Miliaraki, Panagiotis Briassoulis, Stavroula Ilia, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
Infectious Diseases and Therapy|February 15, 2021
The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 PatientsAlberto E Maraolo, Silvia Corcione, Adriano Grossi, et al.
The Lancet. Infectious Diseases|August 24, 2013
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesL Silvia Munoz-Price, Laurent Poirel, Robert A Bonomo, et al.
Microbiology Spectrum|May 23, 2023
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumanniiHadas Kon, Amichay Hameir, Amir Nutman, et al.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
Pageof 11